Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer

Inclusion Criteria:

Willing and able to provide informed consent;
Men, 18 years of age or older;
Histologically or cytologically confirmed adenocarcinoma of the prostate;
Ongoing androgen deprivation therapy

Exclusion Criteria:

Severe concurrent disease;
Known or suspected brain metastasis;
History of another malignancy within the previous 5 years;
Prior treatment with docetaxel-based chemotherapy